Search for: "Hoffmann-La Roche"
Results 21 - 40
of 180
Sort by Relevance
|
Sort by Date
18 Aug 2019, 5:07 am
Hoffmann-La Roche AG ("Roche"), the owner of the [read post]
5 Aug 2019, 4:06 pm
Hoffmann-La Roche AG and another [2019] EWHC 1520 (Pat) (20 June 2019) An "Arrow declaration" is a declaration that a product or process was known or obvious at a particular date and therefore could not fall within the claims of a [read post]
21 May 2019, 12:40 pm
Following Health Canada’s request, [Hoffmann-La Roche Limited] performed a cumulative, comprehensive assessment of serious hepatic injury including hepatic failure reported with ACTEMRA across all available clinical and post-marketing data sources, including data from the Food and Drug Administration Adverse Event Reporting System (FAERS) and Eudravigilance (EV) databases and from the literature. [read post]
10 May 2019, 8:45 am
Sophie Lawrance, Noel Watson-Doig, Edwin Bond, and Matthew Hunt describe Coty, Hoffmann-La Roche II, EAEPC, Commission SEP Communication and others: A Survey of Developments at the Intersection between Competition Law and IP Law in the Past Year. [read post]
26 Feb 2019, 7:46 am
The December 10 order is incompatible with Hoffmann-La Roche and with what we hold in this opinion regarding notice. [read post]
25 Feb 2019, 7:22 am
” Hoffmann-La Roche Inc. v. [read post]
20 Dec 2018, 9:22 am
Schnitzer, of Hoffman-La Roche. 1955. [read post]
12 Nov 2018, 1:12 pm
Hoffmann-La Roche Ltd. v. [read post]
12 Oct 2018, 1:24 pm
In Hoffmann-La Roche, 748F.3d at 1329, the court considered whether it would havebeen obvious at the time of invention to select a once amonth oral dosing regimen of 150mg of ibandronate totreat osteoporosis. [read post]
31 Jul 2018, 11:45 am
Sophie Lawrance, Edwin Bond and Matthew Hunt recap AKKA/LAA, Coty, Hoffmann La Roche II and Others: A Survey of Cases at the Intersection between Competition Law and IP Law in the Past Year. [read post]
4 Jun 2018, 5:00 am
Mario Todino and Niccolò Colombo have written on Case C-179/16 Hoffmann-La Roche: By Object Restrictions Still Bitter Pills to Swallow? [read post]
5 Jul 2017, 1:06 pm
Hoffmann-La Roche, Inc., 511 F.3d 506, 509 (5thCir. 2007); Elbaor v. [read post]
10 Apr 2017, 3:47 am
The drug was originally developed by Hoffmann-La Roche labs and was used to treat a severe skin condition known as nodular acne. [read post]
27 Sep 2016, 10:16 am
Hoffmann-La Roche Ltd. v. [read post]
1 Apr 2016, 1:01 pm
Hoffmann-La Roche, Inc., 99 N.J. 284, 285 (1985). [read post]
22 Mar 2016, 6:12 am
Hoffmann-La Roche AG and Genentech Inc. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences. [read post]
14 Mar 2016, 3:23 am
Hoffmann-La Roche AG and Genentech Inc. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences. [read post]
9 Mar 2016, 11:43 am
Hoffmann-La Roche Inc., 541 F.3d 1115, 1122 (Fed. [read post]
7 Mar 2016, 1:55 am
Hoffmann-La Roche AG and Genentech Inc. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences.Never too late 83 [week ending on Sunday 14 February] – Indigenous IP | Arnold J's latest judgment flags down the iconic London black cab | Life of a national/EU trade mark ... in a map | A comprehensive… [read post]
29 Feb 2016, 11:27 pm
Hoffmann-La Roche AG and Genentech Inc. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences.Never too late 83 [week ending on Sunday 14 February] – Indigenous IP | Arnold J's latest judgment flags down the iconic London black cab | Life of a national/EU trade mark ... in a map | A comprehensive… [read post]
